redOx⇌KCL Publications

13. Oxali(IV)Fluors: Fluorescence Responsive Oxaliplatin(IV) Complexes Identify a Hypoxia-Dependent Reduction in Cancer Cells M. H. C. Boulet, H. R. Bolland, E. M. Hammond, A. C. Sedgwick. J Am Chem Soc. 2023 DOI: 10.1021/jacs.3c03320

12. Antibody-based imaging of bioreductive prodrug release in hypoxia Ç. Tosun, M. Mallerman, A. L. D. Wallabregue, S. Phillips, C. M. Edwards, S. J. Conway, E. M. Hammond. ChemRxiv, 2023 DOI: 10.26434/chemrxiv-2023-9n5s0

11. Two color imaging of different hypoxia levels in cancer cells. A. Wallabregue, H. Bolland, S. Faulkner, E. M. Hammond, S. J. Conway. J. Am. Chem. Soc., 2023 145, 2572

10. A fluorescent probe strategy for the detection and discrimination of hydrogen peroxide and peroxynitrite in cells. H. Bolland, E. M. Hammond, A. C. Sedgwick. Chem Commun (Camb). 2022 58,10699

9. Identification of histone peptide binding specificity and small molecule ligands for the bromodomains of TRIM33α and TRIM33β A. R. Sekirnik, J. K. Reynolds, L. See, J. P. Bluck, A. R. Scorah, C. Tallant, B. Lee, K. B. Leszczynska, R. L. Grimley, R. I. Storer, M. Malattia, S. Crespillo, S. Caria, S. Duclos, E. M. Hammond, S. Knapp, G. M. Morris, F. Duarte, P. C. Biggin, S. J. Conway. ACS Chem. Biol., 2022 17, 2753

8. Measuring ROS and redox markers in plant cells. S. Akter, M. S. Khan, E. N. Smith, E. Flashman. RSC Chemical Biology, 2021 2, 1384

7. Cell-permeable lanthanide-platinum(IV) anti-cancer prodrugs. K. Yao, G. Karunanithy, A. Howarth, A. L. Thompson, K. E. Christensen, A. J. Baldwin, S. Faulkner, N. J. Farrer, Dalton Trans., 2021 50, 8761

6. Zap-Pano: a photocaged pro-drug of the KDAC inhibitor panobinostat. K. S. Troelsen, E. D. D. Calder, A. Skwarska, D. Sneddon, E. M. Hammond, S. J. Conway. ChemMedChem. 2021 16, 3691

5. Controlling intramolecular interactions in the design of selective, high-affinity ligands for the CREBBP bromodomain. M. Brand, J. Clayton, M. Moroglu, M. Schiedel, S. Picaud, J. P. Bluck, A. Skwarska, H. Bolland, A. K. N. Chan, C. M. C. Laurin, A. R. Scorah, L. See, T. P. C. Rooney, K. H. Andrews, O. Fedorov, G. Perell, P. Kalra, K. B. Vinh, W. A. Cortopassi, P. Heitel, K. E. Christensen, R. I. Cooper, R. S. Paton, W. C. K. Pomerantz, P. C. Biggin, E. M. Hammond, P. Filippakopoulos, S. J. Conway. J. Med. Chem., 2021 64, 10102

4. Links between the unfolded protein response and the DNA damage response in hypoxia: a systematic review. H. Bolland, T. S. Ma, S. Ramlee, K. Ramadan, E. M. Hammond. Biochem Soc Trans., 2021 49, 1251

3. Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. A. Skwarska, E. D. D. Calder, D. Sneddon, H. Bolland, M. L. Odyniec, I. N. Mistry, J. Martin, L. K. Folkes, S. J. Conway, E. M. Hammond. Cell Chem Biol, 2021 28, 1258.

2. Pharmacological inhibition of ATR can block autophagy through an ATR-independent mechanism. E. Bowler, A. Skwarska, J. D. Wilson, S. Ramachandran, H. Bolland, A. Easton, M-S.Hwang, K. B. Leszczynska, S. J. Conway, E. M. Hammond. iScience, 2020 101668

1. Hypoxia-activated pro-drugs of the KDAC inhibitor vorinostat (SAHA). E. D. D. Calder, A. Skwarska, I. N. Mistry, D. Sneddon, S. J. Conway, E. M. Hammond. Tetrahedron, 2020, 76, 131170 (Invited submission in honour of Prof. Steve Davis)